/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

BEYOND AIR INC Share Price Today: Live Updates & Key Insights

BEYOND AIR INC share price today is $0.82, up 0.86%. The stock opened at $0.8126 against the previous close of $0.8033, with an intraday high of $0.8165 and low of $0.8.

BEYOND AIR INC Share Price Chart

style
pb-0

BEYOND AIR INC

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

BEYOND AIR INC Share Price Performance

$0.82 0.0086(0.86%) XAIR at 13 Mar 2026 03:56 PM Medical Devices
Lowest Today 0.8
Highest Today 0.8165
Today’s Open 0.8126
Prev. Close 0.8033
52 Week High 6.44
52 Week Low 0.67
Day’s Range: Low 0.8 High 0.8165
52-Week Range: Low 0.67 High 6.44
1 day return -
1 Week return +1.28
1 month return -21.37
3 month return -19.82
6 month return -66.67
1 year return +221.98
3 year return -87.34
5 year return -86.93
10 year return -

BEYOND AIR INC Institutional Holdings

Alyeska Investment Group, L.P. 5.53

Balyasny Asset Management LLC 4.41

Bleichroeder LP 0.82

Vanguard Group Inc 0.57

Fidelity Extended Market Index 0.42

Geode Capital Management, LLC 0.41

Vanguard Institutional Extnd Mkt Idx Tr 0.30

WEALTH EFFECTS LLC 0.30

BlackRock Inc 0.21

Virtu Financial LLC 0.20

Baldwin Brothers Inc 0.14

Fidelity Total Market Index 0.08

Advisor Group Holdings, Inc. 0.08

Spartan Extended Market Index Pool F 0.05

Fidelity Series Total Market Index 0.04

Spartan Total Market Index Pool G 0.03

Blackrock Extended Mkt Fund CF 0.03

Extended Equity Market Fund K 0.03

Citigroup Inc 0.02

Northern Trust Extended Eq Market Idx 0.02

NT Ext Equity Mkt Idx Fd - L 0.02

NT Ext Equity Mkt Idx Fd - NL 0.02

PFS Partners, LLC 0.02

Fidelity Nasdaq Composite Index 0.02

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.02

Advisory Services Network, LLC 0.01

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.01

Sontag Advisory LLC 0.01

Group One Trading, LP 0.01

Fortitude Family Office LLC 0.01

Vanguard U.S. Eq Idx £ Acc 0.01

Mccormack Advisors International 0.00

Goss Wealth Management LLC 0.00

State St US Extended Mkt Indx NL Cl C 0.00

Extended Equity Market Fund M 0.00

NT Quality SCC US Fund - L 0.00

NT Quality Small Cap Core 0.00

SSgA U.S. Total Market Index Strategy 0.00

Bank of America Corp 0.00

JONES FINANCIAL COMPANIES LLLP 0.00

BEYOND AIR INC Market Status

Strong Buy: 1

Buy: 3

Hold: 1

Sell: 0

Strong Sell: 0

BEYOND AIR INC Fundamentals

Market Cap 8.46 M

PB Ratio 1.0597

PE Ratio 0.0

Enterprise Value 20.53 M

Total Assets 30.06 M

Volume 91620

BEYOND AIR INC Company Financials

Annual Revenue FY25:3705000 3.7M, FY24:1159000 1.2M, FY23:59000 0.1M, FY22:0 0.0M, FY21:873190 0.9M

Annual Profit FY25:-1663000 -1.7M, FY24:-1307000 -1.3M, FY23:-555000 -0.6M, FY22:null 0.0M, FY21:873190 0.9M

Annual Net worth FY25:-46625000 -46.6M, FY24:-60242000 -60.2M, FY23:-55816000 -55.8M, FY22:-56252000 -56.3M, FY21:-23516357 -23.5M

Quarterly Revenue Q4/2025:2194000 2.2M, Q3/2025:1818000 1.8M, Q2/2025:1760000 1.8M, Q1/2025:1152000 1.2M, Q4/2024:1072000 1.1M

Quarterly Profit Q4/2025:300000 0.3M, Q3/2025:-298000 -0.3M, Q2/2025:156000 0.2M, Q1/2025:-32000 -0.0M, Q4/2024:-215000 -0.2M

Quarterly Net worth Q4/2025:-7336000 -7.3M, Q3/2025:-7940000 -7.9M, Q2/2025:-7691000 -7.7M, Q1/2025:-8034000 -8.0M, Q4/2024:-13032000 -13.0M

About BEYOND AIR INC & investment objective

Company Information Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM) at home. In addition, the company develops ultra-high concentration (UNO) that is in Phase 1 clinical trial to treat multiple solid and cutaneous tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions and autism spectrum disorder. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.

Organisation Medical Devices

Employees 61

Industry Medical Devices

CEO Mr. Steven Adam Lisi

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow